skip to Main Content

Silencing RNA nanotherapy shows promise against pancreatic cancer

Silencing RNA nanotherapy shows promise against pancreatic cancer
Despite advances in cancer survival, more than 90 percent of people with pancreatic cancer die within five years. Most patients with pancreatic tumors (and half of those with colorectal cancers) carry a mutation in the KRAS gene, which normally controls cell growth and death.

The KRAS oncogene was discovered more than 35 years ago and is considered one of the most desirable targets in cancer biology—particularly for cancers (like pancreatic) often diagnosed late and in desperate need of improved therapies to prolong survival. Read more . . . 


Back To Top